Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IgG1-DE-vcMMAE
- Development stage
- Preclinical
- Lead developer
- University Medical Center Schleswig-Holstein
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IgG1-DE-vcMMAE is a non-targeting isotype control antibody-drug conjugate (ADC) utilized in preclinical oncology research. It consists of a human IgG1 antibody backbone that has been Fc-engineered with S239D and I332E (DE) mutations to enhance Fc-mediated effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC). This antibody is conjugated to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) through a cathepsin-cleavable valine-citrulline (vc) linker. In experimental settings, such as the study of CD7-targeted ADCs for T-cell acute lymphoblastic leukemia (T-ALL), IgG1-DE-vcMMAE serves as a critical negative control to differentiate between target-mediated antileukemic activity and non-specific effects related to the payload or the engineered Fc region.
- Other names
- isotype control ADCcontrol ADC
02
Targets
C1Q (Complement C1q)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on IgG1-DE-vcMMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IgG1-DE-vcMMAE.